Black Diamond Therapeutics, Inc. BDTX
We take great care to ensure that the data presented and summarized in this overview for Black Diamond Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding BDTX
View all-
T. Rowe Price Investment Management, Inc. Baltimore, MD10.7MShares$45.2 Million0.02% of portfolio
-
Vestal Point Capital, LP New York, NY5.55MShares$23.4 Million0.95% of portfolio
-
Nea Management Company, LLC Timonium, MD4.45MShares$18.7 Million1.03% of portfolio
-
Black Rock Inc. New York, NY3.22MShares$13.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.19MShares$9.22 Million0.0% of portfolio
-
Tang Capital Management LLC San Diego, CA2.07MShares$8.72 Million0.35% of portfolio
-
Marshall Wace, LLP London, X01.3MShares$5.47 Million0.01% of portfolio
-
Siren, L.L.C. New York, NY1.05MShares$4.41 Million0.16% of portfolio
-
Arrowstreet Capital, Limited Partnership Boston, MA897KShares$3.78 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny850KShares$3.58 Million0.0% of portfolio
Latest Institutional Activity in BDTX
Top Purchases
Top Sells
About BDTX
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 driver mutations. The company is also developing BDTX-1535, a brain-penetrant inhibitor of EGFR mutations, including canonical, intrinsic resistance, and acquired resistance mutations; and BDTX-4933, a brain-penetrant inhibitor of oncogenic BRAF class I, II and III alterations. It has a strategic partnership with OpenEye Scientific Software, Inc. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Transactions at BDTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 12
2025
|
Prakash Raman |
BUY
Grant, award, or other acquisition
|
Direct |
4,665
+13.07%
|
$9,330
$2.76 P/Share
|
|
Dec 12
2025
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
5,208
+5.67%
|
$10,416
$2.76 P/Share
|
|
Sep 19
2025
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
4,291
+5.01%
|
$12,873
$3.35 P/Share
|
|
Sep 19
2025
|
Prakash Raman |
BUY
Grant, award, or other acquisition
|
Direct |
3,843
+12.72%
|
$11,529
$3.35 P/Share
|
|
Jun 20
2025
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
6,170
+7.41%
|
$12,340
$2.33 P/Share
|
|
Jun 20
2025
|
Prakash Raman |
BUY
Grant, award, or other acquisition
|
Direct |
5,526
+19.7%
|
$11,052
$2.33 P/Share
|
|
Mar 21
2025
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
7,646
+9.72%
|
$7,646
$1.88 P/Share
|
|
Mar 21
2025
|
Prakash Raman |
BUY
Grant, award, or other acquisition
|
Direct |
6,848
+28.72%
|
$6,848
$1.88 P/Share
|
|
Mar 19
2025
|
Growth N V Biotech > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
5,784,292
-14.57%
|
$11,568,584
$2.07 P/Share
|
|
Jan 30
2025
|
Brent Hatzis Schoch |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+47.35%
|
-
|
|
Jan 30
2025
|
Erika Jones |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+46.83%
|
-
|
|
Jan 30
2025
|
Elizabeth Buck CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+30.59%
|
-
|
|
Jan 30
2025
|
Sergey Yurasov CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+50.0%
|
-
|
|
Jan 30
2025
|
Mark A. Velleca PRESIDENT & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
75,000
+38.16%
|
-
|
|
Dec 13
2024
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
5,750
+8.32%
|
$11,500
$2.5 P/Share
|
|
Dec 13
2024
|
Shannon Campbell |
BUY
Grant, award, or other acquisition
|
Direct |
4,500
+33.67%
|
$9,000
$2.5 P/Share
|
|
Dec 13
2024
|
Prakash Raman |
BUY
Grant, award, or other acquisition
|
Direct |
5,150
+33.67%
|
$10,300
$2.5 P/Share
|
|
Sep 20
2024
|
Ali Behbahani |
BUY
Grant, award, or other acquisition
|
Direct |
3,007
+4.96%
|
$12,028
$4.78 P/Share
|
|
Sep 20
2024
|
Shannon Campbell |
BUY
Grant, award, or other acquisition
|
Direct |
2,354
+35.04%
|
$9,416
$4.78 P/Share
|
|
Sep 20
2024
|
Prakash Raman |
BUY
Grant, award, or other acquisition
|
Direct |
2,694
+35.04%
|
$10,776
$4.78 P/Share
|
Last 12 Months Summary
| Grant, award, or other acquisition | 419K shares |
|---|
| Open market or private sale | 5.78M shares |
|---|